Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › PEPG

PepGen

PEPG Rare disease Lead: Phase 2 2 Biotech Distilled articles ↓ 15 filings & releases ↓ Cash $22.8M (Jun 30, 2026) ↓ 2 verdicts ↓ 2 timing quotes ↓
Neurology Nucleic Acid

Market cap $171M 69.3M shares (10-Q, Aug 2, 2026) × $2.47 close Nov 6, 2026

Most recent annual filing: 2026-03-04

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. PGN-EDODM1 toplineNov 2026PGN-EDODM1 topline, Nov 2026, thesis-defining
  2. PGN-EDODM1 readout1H 2027PGN-EDODM1 readout, 1H 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (1 active programs)

Technology platforms

EDO

Enhanced Delivery Oligonucleotide platform leveraging cell-penetrating peptides (CPPs) conjugated to oligonucleotide therapeutics (PPMOs) to optimize tissue penetration, cellular uptake, and nuclear delivery; focus on neuromuscular and neurologic diseases including myotonic dystrophy type 1

Discontinued (1)

Capital (as filed)

Cash
$22.8M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$94.5M Jun 30, 2026
Operating cash flow
−$15.8M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$117M cash, runway Q4 2027 per the update of Aug 6, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (2)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on PepGen, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-05-29 Watch PepGen (PEPG) — Scientific Deep Dive for PGN-EDODM1 and the EDO Platform Despite differentiated chemistry and a $12B M&A precedent, the 5 mg/kg MAD ITT miss, unresolved FDA partial clinical hold, kidney safety signal, late competitive position, and loaded $400M shelf warrant waiting for the 2H 2026 10 mg/kg readout before taking a position.
  2. 2026-08-07 Speculative buy speculative UPDATE: PepGen (PEPG) - The DSMB Blinked First DSMB clearance to escalate to 12.5 mg/kg with no protocol changes de-risks the kidney safety trapdoor, the dilution gun is no longer cocked with runway into Q4 2027, and the binary 10 mg/kg readout now has a firm November 2026 date — warranting a small, option-like speculative position.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (15)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)